Trials / Terminated
TerminatedNCT03859869
A Study of Creon (Pancrelipase) in Resected and Non-resected Pancreatic Cancer Participants With Exocrine Pancreatic Insufficiency (EPI)
Creon (Pancrelipase) Therapy for Subjects With Exocrine Pancreatic Insufficiency (EPI) Due to Pancreatic Cancer: A Double-blind, Randomized, Parallel Design With 2 Dose Cohorts of Pancrelipase in Resected Pancreatic Cancer Subjects and an Open-label Single Dose Cohort in Non-resected Pancreatic Cancer Subjects
- Status
- Terminated
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 1 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 21 Years
- Healthy volunteers
- Not accepted
Summary
This is a study in participants with Exocrine Pancreatic Insufficiency (EPI) due to pancreatic cancer. This study will include resected participants who are post pancreatic cancer surgery, and an additional cohort in non-resected participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pancrelipase | Pancrelipase is administered orally as capsules with a meal or snack |
| DRUG | Placebo | Placebo is administered orally as capsules with a meal or snack |
Timeline
- Start date
- 2020-02-25
- Primary completion
- 2022-03-23
- Completion
- 2022-03-23
- First posted
- 2019-03-01
- Last updated
- 2023-06-05
- Results posted
- 2023-06-05
Locations
33 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03859869. Inclusion in this directory is not an endorsement.